Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results.

We conducted a prospective observational study on 24 CF patients with CF-related diabetes requiring insulin therapy, with the aim to evaluate the effectiveness of ETI on glucose metabolism, glucose variability and body composition. After six months of treatment, HbA1c and coefficient of variation, measured through flash or continuous glucose monitoring, significantly decreased (median changes: -0.5, P = 0.029 and -6.3, P = 0.008, respectively), despite unchanged insulin requirements.

Over the treatment period, percent of fat mass increased by a median value of 3% (p = 0.029).

囊性纤维化跨膜电导调节剂（CFTR）调节剂是一组用于治疗囊性纤维化（CF）的新药，elexacaftor + tezacaftor + ivacaftor（ETI）三联疗法已被批准作为治疗以下患者的首选疗法：至少 1 个 F508del 变体副本。关于 CFTR 调节剂对葡萄糖代谢影响的数据仅限于小型研究，结果相互矛盾。

我们对 24 名需要胰岛素治疗的 CF 相关糖尿病患者进行了一项前瞻性观察研究，旨在评估 ETI 对糖代谢、血糖变异性和身体成分的有效性。 治疗六个月后，尽管胰岛素需求量不变，但通过快速或连续血糖监测测量的 HbA1c 和变异系数显着下降（中位变化：分别为 -0.5，P  = 0.029 和 -6.3，P = 0.008）。

在治疗期间，脂肪量百分比中值增加了 3% ( p  = 0.029)。